Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 13/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valsartan SCHEMBL2328 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2542 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2329 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408289 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121526 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121527 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL20527991 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125809-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191907-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-09-30 | — | — | WO | disclosed |
| CN-110123778-A | A kind of valsartan capsule and preparation method thereof | 南京致中生物科技有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-109953969-A | A kind of preparation method of valsartan amlodipine piece | 湖南千金协力药业有限公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-109574943-A | The preparation method of Valsartan nitrous clout | 浙江工业大学上虞研究院有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109432034-A | A kind of valsartan amlodipine tri-layer tablets and preparation method thereof | 乐普制药科技有限公司 | 2019-03-08 | — | — | CN | disclosed |
| WO-2019014420-A1 | COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS | AZHC, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| CN-108553435-A | A kind of Valsartan piece and preparation method thereof | 华益药业科技(安徽)有限公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-108084058-A | A kind of preparation method of LCZ696 intermediates | 江苏中邦制药有限公司 | 2018-05-29 | — | — | CN | disclosed |
| EP-3233916-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20110044935-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CARDIOMYOPATHY AND HEART DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-02-24 | — | — | US | disclosed |
| EP-1799263-A4 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008052184-A1 | LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, INCLUDING WITH OTHER PHARMACOLOGIC PREPARATION, CAPABLE OF ADMINISTRATION AS AN ORAL, TOPICAL, INTRAORAL OR TRANSMUCOSAL PREPARATION, FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN | GUILFORD TIMOTHY F (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007053810-A9 | LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, INCLUDING WITH OTHER PHARMACOLOGIC PREPARATION, CAPABLE OF ADMINISTRATION AS AN ORAL, TOPICAL, INTRAORAL OR TRANSMUCOSAL, PREPARATION, FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN | GUILFORD F TIMOTHY (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1799263-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | The President and Fellows of Harvard College (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007053810-A2 | LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, INCLUDING WITH OTHER PHARMACOLOGIC PREPARATION, CAPABLE OF ADMINISTRATION AS AN ORAL, TOPICAL, INTRAORAL OR TRANSMUCOSAL, PREPARATION, FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN | GUILFORD F TIMOTHY (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006031931-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2003089417-A1 | NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2’-(1H-TETRAZOL-5-YL-)- BIPHENYL-4-YL METHYL] AMINE (VALSARTAN) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-10-30 | — | — | WO | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | AGTR1 1893/4885LTB4R2 451/4885ABCB11 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.